Biological Markers to Identify Early Sepsis and Acute Lung Injury

NCT00825357 | Completed

• 1 other identifier: CM-IRB09509002
• Study Type: observational
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

There are no clear markers to identify sepsis and acute lung injury at early stage in clinical settings which would result in improved survival of the patients. In collaboration with the research team led by Dr. Zhang at St. Michael's Hospital, Toronto, we have initiated a pilot study looking for biological markers to detect severe sepsis and ARDS. We have found that human neutrophils peptides (a-defensins), certain coagulation variables and cytokine levels are very sensitive markers to differentiate severe sepsis, ARDS from cardiovascular diseases in ICU patients. These findings may provide valuable information for therapeutic guideline in clinical practice. The present study will focus on testing 'biological markers' to identify patients with sepsis and acute lung injury. We will examine the roles of three components of markers including inflammation, neutrophil activation and coagulation. We are hoping that this proposed translational research will help develop novel therapeutic strategy in sepsis and acute lung injury patients.

Conditions

Sepsis; Acute Lung Injury

Keywords

biological markers; sepsis; acute lung injury

Outcome Measures

Primary Outcomes (1)

• The present study will focus on testing 'biological markers' to identify patients with sepsis and acute lung injury in early stage.

  72 hrs

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients admitted to ICU and age ≧18-year-old.

You may qualify if:

• Meet diagnostic criteria of ≧2 SIRS or acute lung injury.
• Get agreement of patient's attending physician and inform consent form patient or family.

You may not qualify if:

• Use Antibiotics over 24 hrs（only SIRS group）.
• Active bleeding.
• Pregnancy.
• Active Cancer (refer to malignancy which is recently diagnosed, under treatment, or relapsed)
• VS or Subject or Family refuse

Sponsors & Collaborators

• Chimei Medical Center: lead

Study Sites (1)

Department of Intensive Care Medicine; Chi Mei Medical Center

Tainan, Taiwan

Location

MeSH Terms

Conditions

Sepsis; Acute Lung Injury

Condition Hierarchy (Ancestors)

Infections; Systemic Inflammatory Response Syndrome; Inflammation; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Lung Injury; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Chief

Study Record Dates

• First Submitted: January 15, 2009
• First Posted: January 21, 2009
• Study Start: September 1, 2006
• Primary Completion: August 1, 2011
• Study Completion: August 1, 2011
• Last Updated: January 28, 2016

Record last verified: 2016-01

Locations

TW (1)